Experimental lung cancer drug shows promise but trial halted early

NCT ID NCT06685718

Terminated Disease control Sponsor: BeOne Medicines Source: ClinicalTrials.gov ↗

First seen Nov 01, 2025 · Last updated May 23, 2026 · Updated 30 times

Summary

This early-stage study tested a new drug, BG-60366, designed to break down a faulty protein (mutant EGFR) that drives growth in some lung cancers. The trial aimed to find a safe dose and see if the drug could shrink tumors in people with advanced non-small cell lung cancer that had stopped responding to other treatments. The study was terminated early, but the results will help researchers understand the drug's safety and potential.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Austin Health

Heidelberg, Victoria, VIC 3084, Australia
Beijing Cancer Hospital

Beijing, Beijing Municipality, 100142, China
Blacktown Cancer and Haematology Centre

Blacktown, New South Wales, NSW 2148, Australia
Cancer Research South Australia

Adelaide, South Australia, SA 5000, Australia
Chungbuk National University Hospital

Cheongju-si, Chungcheongbukdo, 28644, South Korea
Dana Farber Cancer Institute

Boston, Massachusetts, 02215-5418, United States
Fondazione Irccs San Gerardo Dei Tintori Sc Oncologia

Monza, 20900, Italy
Fondazione Policlinico Universitario Agostino Gemelli

Roma, 00168, Italy
Guangdong Provincial Peoples Hospital Huifu Branch

Guangzhou, Guangdong, 510120, China
H Puerta de Hierro Majadahonda

Majadahonda, 28222, Spain
Harbour Cancer and Wellness

Auckland, 1023, New Zealand
Hospital Universitario 12 de Octubre

Madrid, 28041, Spain
Hospital Universitario Vall Dhebron

Barcelona, 08035, Spain
Liverpool Hospital

Liverpool, New South Wales, NSW 2170, Australia
Memorial Sloan Kettering Cancer Center Mskcc

New York, New York, 10065-6800, United States
Ohio State University

Columbus, Ohio, 43210-1132, United States
Peter Maccallum Cancer Centre

Melbourne, Victoria, VIC 3000, Australia
Princess Alexandra Hospital

Woolloongabba, Queensland, QLD 4102, Australia
Samsung Medical Center

GangnamGu, Seoul Teugbyeolsi, 06351, South Korea
Seoul National University Hospital

Seoul, Seoul Teugbyeolsi, 03080, South Korea
Severance Hospital Yonsei University Health System

SeodaemunGu, Seoul Teugbyeolsi, 03722, South Korea
Shanxi Bethune Hospital

Taiyuan, Shanxi, 030032, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicineqiantang Branch

Hangzhou, Zhejiang, 310018, China
The Second Affiliated Hospital of Nanchang University

Nanchang, Jiangxi, 330006, China
The Tumor Hospital Affiliated to Guangxi Medical Universitywuxiang Branch

Nanning, Guangxi, 530201, China
The University of Texas Md Anderson Cancer Center

Houston, Texas, 77030-4009, United States
Tianjin Medical University Cancer Institute and Hospital

Tianjin, Tianjin Municipality, 300060, China
University of Colorado

Denver, Colorado, 80202-1702, United States
Washington University School of Medicine Siteman Cancer Center

St Louis, Missouri, 63110-1032, United States

Conditions

Explore the condition pages connected to this study.

EGFR ACTIVATING MUTATION EGFR ACTIVATING MUTATION EGFR MUTATION-RELATED TUMORS LUNG CANCER NON-SMALL CELL LUNG CANCER NON-SMALL CELL LUNG CANCER NSCLC NSCLC (NON-SMALL CELL LUNG CARCINOMA)